Relmada Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 20
- Market Cap
- $82M
- Website
- http://www.relmada.com
- Introduction
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
- Conditions
- Major Depressive DisorderDepression
- Interventions
- Drug: PlaceboDrug: REL-1017
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT06011577
- Locations
- 🇺🇸
Relmada Site, Seattle, Washington, United States
Individual Patient Esmethadone (REL-1017) Expanded Access Program
- Conditions
- Major Depressive DisorderDepression
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Registration Number
- NCT06009003
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: REL-1017Drug: Placebo
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT05081167
- Locations
- 🇺🇸
Relmada Site, Austin, Texas, United States
Safety of REL-1017 for Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: REL-1017
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 627
- Registration Number
- NCT04855760
- Locations
- 🇺🇸
Relmada Site, Staten Island, New York, United States
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
- Conditions
- DepressionMajor Depressive Disorder
- Interventions
- Drug: REL-1017Drug: Placebo
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT04855747
- Locations
- 🇺🇸
Relmada Site, Everett, Washington, United States
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: PlaceboDrug: REL-1017
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04688164
- Locations
- 🇺🇸
Relmada Site, Austin, Texas, United States
Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)
- Conditions
- Neuropathic Pain
- Interventions
- Drug: PlaceboDrug: REL-1017
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03637361
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)
- Conditions
- Neuropathic Pain
- Interventions
- Drug: PlaceboDrug: REL-1017
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03638869
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
- Conditions
- Depressive Disorder, MajorDepressive Disorder, Treatment-Resistant
- Interventions
- Drug: REL-1017Drug: Placebo
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT03051256
- Locations
- 🇺🇸
Pillar Clinical Research, LLC, Richardson, Texas, United States
🇺🇸Innovative Clinical Research, Inc, Hialeah, Florida, United States
🇺🇸St. Louis Clinical Trials, LLC, Saint Louis, Missouri, United States